Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.
News & Analysis: NGM Biopharmaceuticals Inc
Shares popped after the clinical-stage biotech reported upbeat clinical results.
Tough industry conditions and company-specific issues hit these stocks.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?